Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Transplantation

Steroid use in HCV-infected liver transplant recipients

The recurrence of hepatitis C in HCV-infected, orthotopic liver transplant recipients is a major problem that can influence the survival of both grafted tissue and patients. Yet the effects of immunosuppression strategies, in particular those of steroids, on disease recurrence remain unclear.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Forman, L. M. et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122, 889–896 (2002).

    Article  Google Scholar 

  2. Berenguer, M. et al. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl. 13, 21–29 (2007).

    Article  Google Scholar 

  3. Lake, J. R. Immunosuppression and outcomes of patients transplanted for hepatitis C. J. Hepatol. 44, 627–629 (2006).

    Article  Google Scholar 

  4. Berenguer, M. et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J. Hepatol. 44, 717–722 (2006).

    Article  CAS  Google Scholar 

  5. Roche, B. et al. Risk factors for hepatitis C recurrence after liver transplantation. J. Viral Hepat. 14 (Suppl. 1), 89–96 (2007).

    Article  Google Scholar 

  6. Lerut, J. et al. Minimization of steroids in liver transplantation. Transpl. Int. 22, 2–19 (2009).

    Article  Google Scholar 

  7. Lladó, L. et al. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl. 14, 1752–1760 (2008).

    Article  Google Scholar 

  8. Klintmalm, G. B. et al. corticosteroid-free immunosuppression with daclizumab in HCV+ liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl. 13, 1521–1531 (2007).

    Article  Google Scholar 

  9. Klintmalm, G. B. et al. Hepatitis C (HCV)-3 study: severe HCV recurrence post liver transplantation (OLT) is decreased in patients treated with mycophenolate mofetil, particularly, in the absence of steroids. Hepatology 48 (Suppl. 4), 338A (2008).

    Google Scholar 

  10. Segev, D. L. et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl. 14, 512–525 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Didier Samuel.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roche, B., Samuel, D. Steroid use in HCV-infected liver transplant recipients. Nat Rev Gastroenterol Hepatol 6, 198–200 (2009). https://doi.org/10.1038/nrgastro.2009.38

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2009.38

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing